Prospective study comparing between the effects of fibrinogen concentrate, and rFVIIa on reduction of blood products transfusion requirements in elective CABG

Prospective study comparing between the effects of fibrinogen concentrate, and recombinant activated factor VII on reduction of blood products transfusion requirements in elective coronary artery bypass surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201901535105039

Enrollment

Registered

2019-01-17

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Haematological Disorders

Interventions

rFVIIa group

Fibrinogen group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled coronary artery bypass grafting (CABG) persistent clinical evidence of bleeding, after heparin reversal, requiring hemostatic therapy, as assessed by anesthetist.

Exclusion criteria

Exclusion criteria: Patients with previous cardiac surgery, patients with previous history of coagulopathy or thromboembolic manifestations. Patients with history of stroke.

Design outcomes

Primary

Measure	Time frame
Blood product transfusion requirement	—

Secondary

Measure	Time frame
Thromboelastography parameters	—

Countries

Egypt

Contacts

Public ContactMoahmed Saleh

Lecturer of anesthesia

drsalehm2002@hotmail.com+201227761463

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026